Search Results - Dafna D. Gladman

Dafna D. Gladman

Dafna Debora Gladman is a Canadian doctor and medical researcher working in the fields of psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis. She is a professor at the University of Toronto Faculty of Medicine and Senior Scientist at the Krembil Research Institute. She is Deputy Director, Centre for Prognosis Studies in the Rheumatic Diseases (part of the University Health Network Arthritis and Autoimmunity Research Centre), Co-Director, Lupus Clinic, Toronto Western Hospital (TWH) and Director, Psoriatic Arthritis Program, Toronto Western Hospital. Provided by Wikipedia
  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis

    Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis by Omar F. Cruz‐Correa, Darshini Ganatra, Ameth N. Garrido, Rohan Machhar, Starlee Lively, Mohit Kapoor, Dafna D. Gladman

    Published 2025-07-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

    Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to con... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu

    Published 2019-05-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

    Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, ran... by Philip J Mease, Dafna D Gladman, Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Joseph C Cappelleri, Thijs Hendrikx, Ming-Ann Hsu, Linda Chen, Elizabeth Kudlacz, Joseph Wu

    Published 2019-06-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: